A man facing progressive muscle decline due to Type 2 spinal muscular atrophy is distressed as the drug company is terminating his free treatment, leaving him with only a month left of coverage. Jeremy Bray, 30, is advocating for the Manitoba government to cover the cost of his vital medication before he loses more independence. Despite already losing mobility in various body parts, including his head, arms, and legs, Bray has seen positive effects from the treatment, such as improved facial expressions and voice strength.
Previously, the Manitoba government intervened to secure free coverage for Bray on compassionate grounds, resulting in notable improvements in his condition. However, the drug manufacturer’s decision to discontinue the coverage has left Bray fearful and devastated. The province’s stance against funding the expensive treatment, priced at approximately $300,000 in the first year, is based on guidance from Canada’s Drug Agency (CDA), which does not recommend the drug for adults over 25 due to the lack of clinical testing in that age group.
Despite requests for a review based on real-world evidence of the drug’s efficacy, the CDA has maintained its position. While Manitoba currently covers the medication for patients under 25, other provinces like Quebec have no age restrictions. Patient advocacy groups have highlighted that some provinces, including Saskatchewan, Alberta, and Ontario, have made exceptions for adult patients based on individual cases. Progressive Conservative Leader Obby Khan believes Manitoba should follow suit and authorize funding for Bray’s treatment.
Roche, the drug company, emphasized the need for sustainable access to medicines and equitable healthcare systems, urging provincial decision-makers to explore alternative funding solutions. Despite the appeals for extended coverage, Health Minister Uzoma Asagwara has reiterated the importance of following expert recommendations and stated that the CDA determines drug accessibility for Canadians. The ongoing debate underscores the challenges faced by patients seeking access to life-changing treatments amidst regulatory constraints.